Regulatory Agencies Review New Therapy for Myasthenia Gravis

Regeneron Pharmaceuticals' investigational therapy, cemdisiran, has been accepted for regulatory review by both the FDA and EMA for generalized Myasthenia Gravis. The FDA granted Priority Review, setting a target action date for November 2026. This siRNA therapy could offer a new treatment option, potentially with less frequent subcutaneous administration.